US OptionsDetailed Quotes

CHRS250117P3000

Watchlist

1.38
0.000.00%

15min DelayClose Jan 17 16:00 ET

0.00High0.00Low

Coherus BioSciences Stock Discussion

Jaguar8

Yesterday 20:00

NEWS

$Coherus BioSciences (CHRS.US)$
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
Wednesday, 22nd January at 7:00 am
– Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate –
– Antitumor activity was observed across both viral and non-viral etiologies –
– Data support continued...

Trytosaveabit

Dec 18, 2024 07:49

New form 4!

$Coherus BioSciences (CHRS.US)$

Zontex

Dec 16, 2024 09:13

$WISeKey (WKEY.US)$ 🙏🏾

Quantum Computing Rebounds: Can the rise continue?

Jaguar8

Dec 3, 2024 16:27

🟢Watchlist Wednesday, December 4. NFA. Check on my previous watchlist. Those without ✅ means they can have delayed market reaction.

Note: The presence of 30 stock picks reflects the reality that not all stocks respond to their press releases immediately. For instance, today’s market activity saw certain high-performing stocks overshadow promising PRs, suggesting that it may take a day, several days, or even a week for the market to fully digest and react. I encourage you to save the watchlist I p...

71698595

Dec 3, 2024 09:18

$Coherus BioSciences (CHRS.US)$ sucks, not looking good anymore

101780576

Dec 3, 2024 09:11

$Coherus BioSciences (CHRS.US)$ bullish finally

Ducati999

Dec 3, 2024 09:05

Squeeze the shorters!

$Coherus BioSciences (CHRS.US)$ once the shorters got squeeze, easily $4. All in now before its too late.

Vexn

Dec 3, 2024 08:25

This stock flying to the moon tonight!
$Coherus BioSciences (CHRS.US)$

Share Your Profit/Loss

Vexn

Dec 3, 2024 08:19

Let's go to the moon!!
$Coherus BioSciences (CHRS.US)$

Share Your Profit/Loss

Jaguar8

Dec 3, 2024 06:08

NEWS

$Coherus BioSciences (CHRS.US)$
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
7 minutes ago, 4:00 AM PST
Via GlobeNewswire
CHRS
Share
- Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI®, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor -
- Proceeds to fund development of key combination programs with LOQTORZI, including casdozokitug, a first-in-class, cli...

No comment yet